NORTHAMPTON, MA / ACCESSWIRE / January 5, 2023 / Quest Diagnostics

It's difficult to overestimate the toll that the COVID-19 pandemic has had on many of our nation's children-academically, socially, developmentally, and emotionally. Quest Diagnostics recognizes the critical role that daily in-school learning plays in helping our kids to overcome the very real challenges they faced with repeated lockdowns, school closings, and the limitations of remote learning.
In our commitment to supporting communities throughout the country, Quest has established multiple initiatives, including:
Quest's "Back to the Classroom" program as well as additional COVID-19 testing initiatives, are also helping college students, faculty, and staff safely return to and stay on campus.
View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.
Contact Info:
Spokesperson: Quest Diagnostics
Website: https://www.3blmedia.com/profiles/quest-diagnostics
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$182.51 |
| Daily Change: | -1.67 -0.91 |
| Daily Volume: | 707,790 |
| Market Cap: | US$20.300B |
October 27, 2025 October 21, 2025 September 23, 2025 September 18, 2025 | |

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load